Lazertinib

A potent, third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations.

https://pubchem.ncbi.nlm.nih.gov/compound/121269225

Small volumes of Lazertinib biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS848624 is a biochemical targeting Lazertinib.